Skip to main content

Table 1 Clinical, biochemical, and therapeutic characteristics of the study patients

From: Effects of preoperative cinacalcet hydrochloride treatment on the operative course of parathyroidectomy and pathological changes in resected parathyroid glands

  All (n = 194) Non-CH group (n = 149) CH group (n = 45) P value
Age, years 55.3 ± 11.7 55.9 ± 11.7 53.3 ± 11.7 0.186
Female (%) 44.3 46.3 37.8 0.313
Dialysis vintage, years 13.0 ± 6.3 13.6 ± 6.4 11.1 ± 5.7 0.020
Underlying diseases (%)
 CGN 54.1 55.0 51.1 0.747
 DMn 8.8 7.4 13.3
 Nephrosclerosis 6.7 6.7 6.7
 PCK 8.8 8.1 11.1
 Others 3.6 3.4 44.4
 Unknown 18.0 19.5 13.3
WBC (/μL) 4916.6 ± 1283.2 4805.4 ± 1253.4 5284.9 ± 1325.9 0.027
Hb (g/dL) 10.6 ± 1.4 10.5 ± 1.4 10.8 ± 1.5 0.265
Plt (× 104/μL) 18. 2 ± 5.3 18.0 ± 5.1 18.8 ± 5.8 0.360
TP (g/dL) 6.3 ± 0.5 6.3 ± 0.5 6.3 ± 0.4 0.385
Alb (g/dL) 3.7 ± 0.3 3.7 ± 0.3 3.7 ± 0.3 0.183
SUN (mg/dL) 64.2 ± 16.5 64.9 ± 16.9 61.8 ± 14.9 0.286
Cr (mg/dL) 12.5 ± 3.0 12.5 ± 3.0 12.6 ± 2.9 0.841
ALP(U/L) 398.5 ± 284.3 386.1 ± 230.7 483.7 ± 413.5 0.419
corrected Ca (mg/dL) 10.1 ± 0.9 10.2 ± 0.8 9.7 ± 1.0 < 0.001
P (mg/dL) 6.3 ± 1.3 6.3 ± 1.3 6.0 ± 1.5 0.168
Intact PTH (pg/mL) 740.1 ± 408.1 764.6 ± 373.9 662.4 ± 498.5 0.210
CaCO3 (%) 47.4 45.0 55.6 0.213
(Dose g/day) 2.7 ± 1.9 2.6 ± 1.9 3.1 ± 1.7 0.252
Non-Ca containing P binders (%) 79.4 83.9 86.7 0.139
Oral VDRA (%) 4.1 4.0 4.4 0.902
Intravenous VDRA (%) 59.8 57.7 66.7 0.283
CH (%) 23.2 0 100
  1. Data are presented as percentage or mean ± standard deviation
  2. CGN chronic glomerulonephritis, DMn diabeteic nephropathy, PCK polycystic kidney disease, WBC white blood cell, Hb hemoglobin, Plt. Platelets, TP total protein, Alb albumin, SUN serum urea nitrogen, Cr creatinine, ALP alkaline phosphatase, Ca calcium, P phosphate, PTH parathyroid hormone, VDRA vitamin D receptor activator, CH cinacalcet hydrochloride